ENTPD1 and neoplasm: The co-expression of CD39 and CD73 by Tregs enables them to enhance the levels of cyclic adenosine monophosphate (cAMP) in anti-tumor T cells through the activation of adenosine receptors, which diminish TCR signaling and IFN-γ production [179, 180].